ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / VIR / financials
MESO (51) REPL (50) COAG (59) ALVO (52) ⌘ Pro Terminal β†’

Vir Biotechnology Inc. (VIR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$11.22 +2.00% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.24

Vir Biotechnology Inc. (VIR) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $1.88B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VIR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is VIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Vir Biotechnology Inc. (NASDAQ: VIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $11.22 (+2.00% 1D, market cap $1.88B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VIR ranks #455 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does VIR compare to MESO and REPL in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VIR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC β€”, cap $1.89B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, VIR leads on earnings multiple (N/A) while VIR leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VIR?
β–Ό

Per VIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001706431), Vir Biotechnology Inc. generated $68.6M in revenue (-7.6% YoY), -$438.0M in net income, and -$396.6M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.24 (+0.17%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (40/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510040
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D
Cash (6)Whales (13)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$13 Bull$10 Base$8 Bear
πŸ“¬ FREE VIR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for VIR)Realized 20D OHLCV Swing Band: Β±12%
Deterministic 5-Pillar Attribution (40/100 Composite)
πŸ” WHY VIR SCORES 40/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+13/20 pts (33% of score)

20D Institutional Volume Accumulation (Β±12% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 2.40 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 4/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
32
Grade E$10.41+1.5% Next Q
Q2 (-2Q)
35
Grade E$10.57+12.9% Next Q
Q3 (-1Q)
37
Grade E$11.93-6% Next Q
Current
40
Grade D-$11.22-7.4% Hist 90D Ξ±
Trajectory: E (32) β†’ D- (40)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a VIR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While VIR currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.02) and Max Pain ($11.78) forces dealer call-delta covering toward $12.80.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VIRβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œVIR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How VIR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$68.6MGross Profit $68.5M (100%)Cost of Sales $26.0KOp Profit $0 (0%)OpEx (R&D/SG&A) $68.5MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $86.2M
FY24
Rev $74.2M
FY25
Rev $68.6M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$68.6M98%-80%-$438.0M-$396.6M-45%
FY 2024$74.2M98%-80%-$522.0M-$453.7M-45%
FY 2023$86.2M92%-80%-$615.1M-$778.8M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VIR)

  • βœ“Walkthrough of VIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
VIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.09%β–² ASCENDING CHANNEL
2026-11-04O $11.30H $11.30L $11.00C $11.22VOL 1.38M
RES: $12.22SUP: $9.31SMA50: $11.02SMA200: $9.60
$12.57$11.01$9.45$7.89$6.34RES $12.22SUP $9.31$11.222026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ VIR Butterfly Map β†’ + Track VIR β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -7.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VIR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for VIR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VIR)

Health Care Rank #455 of 1015 βš”οΈ MESO vs VIR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (VIR vs. MESO, REPL, COAG, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vir Biotechnology Inc. (VIR) ranks #455 by composite RQD confidence (40/100, grade D-) and #261 by equity capitalization ($1.88B). Within this direct 5-issuer industry benchmark cohort, VIR leads on earnings valuation at N/A trailing P/E, while VIR leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. COAG currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with VIR at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VIR ACTIVE
Vir Biotechnology Inc.
D- 40/100 β€” 96.0% -35.0% +2.00% $1.88B Benchmark Subject
MESO
Mesoblast Limited
D 51/100 β€” β€” β€” +1.58% $1.89B /meso-vs-vir β†’
REPL
Replimune Group Inc.
D 50/100 β€” β€” -35.0% +5.95% $1.85B /repl-vs-vir β†’
COAG
Hemab Therapeutics Holdings Inc.
C- 59/100 β€” β€” β€” +4.66% $1.92B /coag-vs-vir β†’
ALVO
Alvotech
D+ 52/100 β€” β€” β€” +1.34% $1.75B /alvo-vs-vir β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001706431 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vir Biotechnology Inc. (VIR) reported GAAP revenue of $68.6M (-7.6% vs. FY2024 revenue of $74.2M , and -20.5% cumulative change since FY2023) , GAAP net income of -$438.0M, operating cash flow of -$391.8M, and free cash flow of -$396.6M (+12.6% YoY). On the balance sheet, VIR closed FY2025 with $1.00B in total assets against $0 in total debt (Altman Z-Score: 2.40, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $68.6M -$438.0M -$391.8M -$396.6M $1.00B β€”
FY2024 (FY) 2024-12-31 $74.2M -$522.0M -$446.4M -$453.7M $1.40B β€”
FY2023 (FY) 2023-12-31 $86.2M -$615.1M -$778.8M -$778.8M β€” β€”

3. VIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vir Biotechnology Inc. (NASDAQ: VIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $11.22 (+2.00% 1D, market cap $1.88B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VIR ranks #455 in composite RQD confidence.

How does VIR compare to MESO and REPL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VIR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, MESO (Mesoblast Limited) holds a D grade (51/100 RQD, P/E N/A, ROIC β€”, cap $1.89B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, VIR leads on earnings multiple (N/A) while VIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VIR?

Per VIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001706431), Vir Biotechnology Inc. generated $68.6M in revenue (-7.6% YoY), -$438.0M in net income, and -$396.6M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VIR trading relative to its 50-day, 200-day, and 52-week technical levels?

VIR last traded at $11.22 (+2.00% on volume of 1,553,560 shares), positioning the stock +1.81% above its 50-day simple moving average ($11.02) and +16.88% above its 200-day simple moving average ($9.60). Across its 52-week range of $4.82 to $12.19, VIR sits at the 86.8% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.0% ($9.87 to $12.57).

Direct Sub-Reports: VIR RQD Cockpit VIR 12M Forecast VIR Earnings & Move VIR Dividends & DRIP VIR Insiders & 13F VIR Whale Options VIR Profit Sankey VIR News & Why
ROARABLE RATING BRIEF β€’ RQD 40/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

VIR β€” Vir Biotechnology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vir Biotechnology Inc. (VIR) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $11.22 (+2.00% 1D, market capitalization $1.88B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of -19.74%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.40, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vir Biotechnology Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile does not describe the company's specific products or customers. The news section references a research and development collaboration with Gilead covering three novel PRO-XTEN dual masked T-cell engagers, and a reported equity stake by Gilead of up to $1.87B. Revenue for FY 2025 was $68.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vir Biotechnology Inc. (VIR) reported $68.6M in annual revenue (up from $74.2M in FY2024, -7.6% YoY) and -$438.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($86.2M revenue, -$615.1M net income) through FY2025, VIR scaled operating cash flow to -$391.8M and free cash flow to -$396.6M, backed by $1.00B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -19.74% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $4.82 – $12.19 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the profile classification and beta of 1.0. A prospective investor should note that the Gilead relationship referenced in the news wire is the only partner-level dependency visible in the data, and its effect on the company's cash runway cannot be quantified from the sources provided.

  • Key Question #1: Can VIR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $68.6M and free cash flow of -$396.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VIR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VIR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vir Biotechnology Inc. (VIR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to VIR Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VIR Bull vs. Bear Conversation Board β€” What's Your Call at $11.22?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VIR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VIR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $14.35 (+27.0%)
πŸ“Œ Pinned Debate

Gilead's equity stake and up-to-$1.87B collaboration for three T-cell engagers is a partner-backed catalyst, and the RQD rating shows s

Gilead's equity stake and up-to-$1.87B collaboration for three T-cell engagers is a partner-backed catalyst, and the RQD rating shows strong institutional accumulation (16/20).. When you look under the hood at VIR, Fundamental Cash Engine is 6/20 with 96.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (13/20) has been quietly accumulating below $12.19. My 12M target is $14.35.

ArenaChamp_24 πŸ‚ BULL

@MidwestValue Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.30 and keeping dry powder in case we test $10.51.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $9.38 (-17.0%)
Spot @ $11.30

Revenue fell from $86.2M to $68.6M over three periods while FCF stayed deeply negative at -$396.6M and ROIC sits at -35%, earning only

Careful chasing VIR at $11.30. Revenue fell from $86.2M to $68.6M over three periods while FCF stayed deeply negative at -$396.6M and ROIC sits at -35%, earning only 6/20 on the Fundamental Cash Engine.. Gross margin is 96.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $9.38 on multiple compression.

LIVE TAPE